What is he best known for?
The fields of study he is best known for:
Xinxin Ding mainly investigates Cytochrome P450, Biochemistry, Microsome, CYP2E1 and Pharmacology.
His Cytochrome P450 research is multidisciplinary, relying on both Mucous membrane of nose and In vivo.
His Mucous membrane of nose study combines topics in areas such as Molecular biology and Gene expression.
The study incorporates disciplines such as Gene isoform, Heme oxygenase and Olfactory mucosa in addition to Microsome.
His research integrates issues of Glutathione, Toxicity and CYP1A2 in his study of CYP2E1.
His Pharmacology research focuses on Drug metabolism and how it relates to Metabolite and Small intestine.
His most cited work include:
- Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts* (654 citations)
- Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. (281 citations)
- Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene: IMPACT ON PLASMA CHOLESTEROL HOMEOSTASIS AND THE FUNCTION AND REGULATION OF MICROSOMAL CYTOCHROME P450 AND HEME OXYGENASE * (182 citations)
What are the main themes of his work throughout his whole career to date?
Cytochrome P450, Molecular biology, Biochemistry, Microsome and Pharmacology are his primary areas of study.
His studies in Cytochrome P450 integrate themes in fields like Toxicity and In vivo.
His work deals with themes such as Allele, Gene expression, Gene, Carcinogen and CYP2A13, which intersect with Molecular biology.
His Microsome study combines topics from a wide range of disciplines, such as Metabolite and Olfactory mucosa.
His Olfactory mucosa research is multidisciplinary, incorporating elements of Isozyme and Mucous membrane of nose.
His Pharmacology research incorporates elements of Xenobiotic, Small intestine, Nicotine and Bronchoalveolar lavage.
He most often published in these fields:
- Cytochrome P450 (65.40%)
- Molecular biology (48.34%)
- Biochemistry (31.75%)
What were the highlights of his more recent work (between 2017-2021)?
- Toxicity (28.91%)
- Pharmacology (26.07%)
- Cytochrome P450 (65.40%)
In recent papers he was focusing on the following fields of study:
His main research concerns Toxicity, Pharmacology, Cytochrome P450, In vivo and Lung.
His research in Toxicity intersects with topics in Endocrinology, Kidney and Vacuolization.
His Cytochrome P450 research includes themes of Glutathione, Gene expression and Drug metabolism.
His In vivo research integrates issues from Molecular biology and In vitro.
His research investigates the connection between Molecular biology and topics such as Carcinogenesis that intersect with issues in Adduct.
His Metabolism study integrates concerns from other disciplines, such as Microsome and Bioavailability.
Between 2017 and 2021, his most popular works were:
- In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library (17 citations)
- In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library (17 citations)
- P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity. (16 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Toxicity, In vivo, Systematic evolution of ligands by exponential enrichment, Molecular biology and Aptamer.
The various areas that he examines in his Toxicity study include Epithelium, Respiratory epithelium and Carcinogen.
His biological study spans a wide range of topics, including Viability assay, In vitro, Cell growth, RNA and Internalization.
Xinxin Ding regularly links together related areas like IC50 in his Systematic evolution of ligands by exponential enrichment studies.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
